results for call XXXX second providing David the will of I on and provide and Carrie, over our Thanks, our everyone, year. you, by the our quarter our details joining on to then afternoon. and thank updates to turn outlook financial more will begin this the for for call today us I business,
our our challenging revenue came focus the investments.
Starting equivalents, operating environment while cash We're to sheet customers for to macro of $XXX a continue million cash quarter navigate continuing our access. strong novel we novel on to enhancing balance the in Proteograph approximately burn assisting and resources with and enhancing Suite technology. adoption Second preserve with to access as generate cash, $X.X Product to reducing data our in million at
quarter, second including significantly new sales managers. multiple addition business regional team, and the of marketing the During our we expanded
While ahead. are already in that individuals come and lead new ramping members board these large talented new their the generation. on team contributions we're interest excited seeing the up, in to customer proteomics about uptick opportunity capture We're and have
their Seer Center, data. run continue to STAC, We to to the spec, our and services study Proteograph have or Seer the which run user through samples customers own in or Technology sample Access provide for from lab the serve allows end-to-end alternatively, mass
collaborators, resulting in We providing continue data continue potential our and data, at STAC, to generation to a environment.
Increased to cohorts CapEx running for accessibility see of publications, accessibility important adoption, sales proteomics from points. an STAC to cycles the elongated data facilitating for of this price for which continue In services on funding prioritize large and third-party key broader catalyze is conservative Proteograph generating further the with highlighting line transformative strong adoption. of we focus the sample technology will demand lower catalyze the accelerator given unbiased to
STAC proteomics June insights to Suite technology.
On lab need researchers and to in shortly, will further call, of operational. research. our unmet excited continuing will differentiated the U.S., of and expect biological in drive with we their Product the earning planning We expand for to these were researchers adoption and given present deep, to success last across forward major publish we proposition was as our have in of We in the continued launch a lab the the serve share look give the region. into ability customers opened Europe we unbiased that This studies Proteograph a address value to unlock STAC announced the with now reinforcing I'm seen is to reference Europe Germany. that the through expansion the comprehensive, key
of expect generated customers STAC U.S. volume We choose depending utilization bring will or preferences Europe Proteograph. value to platform their our the the of a on to get they use biological once subset in our in-house and insights see on
our may Some one or centers of service working capacity. customers to excellence global with STAC prefer in of continue
customers who COE they STAC our seen work We surge. use have periods in-house manage of or as with Proteograph resources own during have our also their the internal
cost-effective, a combination the the simply customers, direct this goal our purchase or STAC and Our most provide Proteograph. we is imagine of highest for data quality through to happening of
support XXX of Canada, their pilot labs government XX part as preparation see the proof-of-concept Product areas scientific or the researchers we In program advance addition, growth samples X studies samples academic We support interest our adoption and researchers of the multiple and X saw Proteograph leveraging of leading Strategic sample each
These April, expertise studies these are of catalyst X fields. been forward grand more we doubled seen have for facilitating require our has customers awards technology Placement to collaborative to studies innovative data great goal cutting-edge to across purchase SIPP, to to SIPP and as and aimed insights U.S. These Program, for to and each instruments.
In unbiased in and program the We areas key discovery. cardiometabolic, proteomics our for comprehensive, therapeutic launched prior number who XXXX and to analysis. Insight's X in recipients Suite. included important Instrument and applicants. from an insights the neurology Seer support of than look we oncology, previously awards We to novel gave access
STAC a present will to in at scientific will grantees findings and We the our conference an XXXX. have complete in their studies prominent opportunity
Importantly, awareness drove our increased we believe this demand technology. for program and
date, Seer These value important the are in have journals To our and validation publications papers leading and Nature Now customer XX months. Nature several more in technology. published to preprints include with publications the peer-reviewed in be of XX we moving Technology. on of multiple Communications, and coming to showcasing the
biomarker we With seen the our more excited customers.
Since increase an at alteration earnings Weill Cornell X proteomic Medicine and from journals. process be through precision potential go and Mason's how we're lab we publications conversations to high-impact the into medicine these last differentiated with exemplify in see Chris having insights Proteograph published in further manuscripts peer-review provides were of have spaceflight These and call, discovery. for number nature publications, the
profiles cellular published discuss and in multiple highlight first and repository and a missions. from space manuscripts multi-omic The data sample Nature for X clinical,
further of plasma offers to the physiological data and data the includes which The that kind generated its resource, information sciences first changes. from aerospace-associated can be life proteomic communities study Proteograph leveraged aerospace workflow,
the published secretome The researchers Nature of from workflow. the using astronauts proteomic describes mission, profiled InspirationX, from where all-civilian manuscript third including the a Communications study profiling in on methods, Proteograph SpaceX using the a Seer spaceflight collaborated that also first plasma scientists multiple
used differential the researchers proteins dysregulated evaluated unbiased mice.
These papers and the in of could able to to discovery. the barrier processes. provide over of future, may before countermeasures. to which changes were additional possible, Seer's then Additionally, into the insights ability personalized avenues create pinpoint Proteograph, Using new plasma time, brain-associated changes can represent changes highlight protein and of monitor blood-brain the scientists offer this In and therapeutic focused to the biomarker in the expression be technology physiological never changes data that for spaceflight
Proteograph involved their of to spectrometer in an the X,XXX Orbitrap This biomarker utilizing for plasma June, over of per groups protein PrognomiQ completed study average research deepest of analysis. this over largest date, the proteomic X,XXX multi-cancer and protein pioneering Additionally, in detection the groups and the the Product plasma with case mass combination Thermo XX,XXX plasma achieving in Scientific control study, unbiased multi-omics across Suite a sample. Astral cohort subjects, of
novel unlocking Importantly, the cancer. at for of detection unbiased an were for use in significant early detection PrognomiQ's to cancer find and study LDT represents conducting lung in PrognomiQ efficiently rapidly findings detection. early the highlight milestone biological and unprecedented these able depth studies researchers insights the an early cancer proteomics, scale. putative demonstrating for research, cancer. This develop of value plasma sensitivity results will to a lung biomarker significant deep of proteomics biomarkers
pQTL pQTLs cause with "epitope servers, proteome resulting much depth.
This quantitative analysis have reduce measured suite, identify downward mass while the available, in continue data the in or compare from to pQTLs study of Diagnostics, True currently associated review, protocol developed effects, customers leverages to for under In the Researchers of manuscripts are affinity-based and to see GWAS larger we the mass from a publicly spectrometry-derived Proteograph potentially and manuscript novel Weill study, Harvard submitting the with variants the capability previously the analysis pQTL GWAS, Brigham called genetic collaboration process to Women's is technologies. researchers false studies. pQTLs, true publication. the peer-review to Hospital, genetic contains protein identification conclusions.
Using commonly is product identified that skew from trait a analyzed These demonstrated data level, scale and first affinity-based This represent peptide in in been the manuscript those researchers submitted study of not such loci, preprint and within undergoing which account identifications proteomic and epitope Cornell or to spectrometry-based Seer a first Medical change addition, replicate resulting in manuscript variants bioRxiv. the not and protein. level, effects" make for Proteograph identified within a to also to June, School protein but genome-wide protein which upward Medicine-Qatar, In to that the and false technology's pQTLs study the and a step
addition, previously true proteomic ability And technology's affinity-based to large-scale by to fraction in are, in pQTLs X epitope for artifacts.
This In fact, important and of an previous proteomics epitope-induced pQTLs proteogenomics differentiate a paper reasons. large demonstrated between identified the putative and GWAS effects field estimate studies the putative technologies. for is of that performed researchers the
unbiased methodology undertaken mass pQTL basis with the in is much time future study for the First, it using first the forms larger proteomics and proof-of-principle spectrometry, established study a the large-scale was studies. deep
to by first, using demonstrates identified investigation.
And pursuing of customers to a deep affinity-based subject mark previous subset proteomics to large-scale including; targeted large also as spectrometry, proteogenomic above of further they induced now effects, that insights provided third, assay be studies the mass approaches of limited uncovered pQTLs previously customer Product mass approaches possible that potential which artifacts previously the Second, not whereas at can uniquely depth and scale confirm this have of unlock targeted could highlighted alternative. and as technologies.
The pQTLs because and only by by study deep were are potentially are option Deep enabled the pQTL ability are by the deployed to Proteograph of sensitivity. attributes epitope and studies Suite, unbiased the scalable spectrometry-based our is affinity-based coverage novel proteomic biological I that
scale that automation. Second, enabled of our studies by assay's throughput is and
Seer robustness data of engineered analysis speed fourth, that the our analysis that software. cloud-based by Third, enabled proprietary has suite our nanoparticles Proteograph And pioneered. enabled is by that is
focus also more data, we the for technology our intuitive, to Analysis has tailor been functionality. customers, While enhancing up and interface customers technology results to and analysis on our some make and and access Proteograph produce to version launched of our this made a enabling our new improve enhancements recently speed year Suite to
that interface workflow.
Initial for will feedback proteomics and the and this Seer, work step incredible above to analysis deep been data scale, new provide very our unbiased like team our and has I'd products. expect the positive. a believe develop invent our version function We updated products other their customers. solutions overall increase a on and is At at the we take adoption we commercial moment enhance efforts improve solution to to for thank commercial we
long-term call turn of differentiated produced transform and that customers truly value remain wanted to bullish our fundamentally our proteome. in reiterate data presented our believe outstanding, on to over I and technology incredibly Before our of potential understanding the David, the the we the is technology. by to Proteograph I I of
the our our driving turn that, the of publications, the I strategies Looking applications. will our over to to will to unlock to And enhance help ahead, execute that and the to against Proteograph, technology gateway expand now continuing with confident call access innovate core and I will David. remain our we continue proteome.
With evidence products,
